If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email email@example.com.
Please tell us what format you need. It will help us if you say what assistive technology you use.
This PGD supports the supply or administration of ciprofloxacin to adults and children for the management of clusters of meningococcal disease, when 2 or more cases are reported in in educational or residential settings. It is valid from 30 August 2019 until 30 August 2022.
This PGD has been revised in August 2019 to clarify that the EU-wide restrictions on the use of ciprofloxacin do not apply to the single dose of ciprofloxacin recommended for chemoprophylaxis of meningococcal disease. An additional dosing schedule for children has been added.
It can be used when a decision has been made by a consultant in health protection or a consultant in public health medicine to offer chemoprophylaxis to:
children and staff of the same preschool group
children of the same school year
children or students who share a common social activity or a group of friends
The PGD template requires further authorisation by a clinical governance or patient safety lead who has designated responsibility for signing PGDs. It is not legal or valid without this local, formal authorisation.
The authorising commissioning body and providers are responsible for the adoption and governance of use of this PGD. Provider organisations and health professionals should check they are using the current version and only work to a legally authorised PGD from their commissioning body.